Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics

Hertz, Barbara; Watabe, Tadashi; Baum, Richard P.

Annals of Nuclear Medicine, 2022, 36, 1007-1009

Number of Access:19（2026-07-28 08:13 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/105196

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
AnnNuclMed_36_1007 pdf None 2.46 MB 9 2026.07.06  

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics
Creator
CreatorName
Hertz, Barbara
NRID
1000090648932 1000090648932
ORCID
0000-0001-8658-2395 0000-0001-8658-2395
researchmap permalink
twosaka2018 twosaka2018
Scopus Author ID
57421862900 57421862900
CreatorName
Watabe, Tadashi
CreatorName
Baum, Richard P.
Description
Hertz B., Watabe T., Baum R.P.. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics. Annals of Nuclear Medicine 36, 1007–1009 (2022); https://doi.org/10.1007/s12149-022-01806-9.
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s12149-022-01806-9
Abstract
In 1942, eighty years ago, Dr. Hertz first conducted radioiodine (RAI) diagnosis and therapy for thyroid disorders followed later by the successful treatment of thyroid cancer patients using RAI. In 2022, memorial 80 years later, alpha emitter astatine (²¹¹At), an analogue for iodine, was successfully administered to a patient with refractory thyroid cancer in Japan as a phase-1 clinical trial (first-in-human). Over the past two decades, the use of ⁶⁸Ga labeled peptides for somatostatin receptor (SSTR)-targeted PET imaging followed by beta or alpha emitters labeled SSTR-analogues for peptide receptor radionuclide therapy (PRRT) has demonstrated remarkable success in the management of neuroendocrine neoplasms. In addition, theranostics targeting prostate-specific membrane antigen (PSMA) have dramatically changed the management and treatment of advanced prostate cancer patients. Novel radionuclides and new targets, ligands targeting the tumor microenvironment, optimized peptides and antibodies, combinations of radioligands with immunotherapy, radioprotectors and radiosensitizers as well as new delivery strategies are currently systematically explored. Now the dream of conquering cancer, that Saul Hertz began eight decades ago is coming to fruition.
Publisher
Springer
Source Title
Annals of Nuclear Medicine
Volume (Issue)
36
Page
1007-1009
Date of Issued
2022-11-08
Language
English
Handle URL
https://hdl.handle.net/11094/105196
PISSN
09147187
eISSN
18646433
Relation.isVersionOf
DOI (Publisher Version)
https://doi.org/10.1007/s12149-022-01806-9
Access Rights
open access
oaire:version
Accepted Manuscript
Category
学術雑誌論文 Journal Article